Outlook

From the latest edition of each brief.

Biotech & Pharma Intelligence

Outlook · No. 052 · · About 2 min read

Our 30, 60 and 90 day view is unchanged from Thursday: rates and a falling market may be the main risk, while drugmakers keep licensing early platforms.

HorizonWhat we expectWhat would change itOdds
30 daysGoal dates on 11.22, 11.27 and 11.30, the CMS negotiated prices due by 11.30 and the 12.09 FOMC, where a hike is priced in futures, as reported, set the news flowA hold or a 50 basis point move at the 12.09 FOMC·
60 daysSUO (12.02), ASH (12.12 to 12.15) and year-end goal dates lead the calendarA biopharma acquisition of $5B or more (call 9 in 15)·
90 daysRAS drugs in pancreatic cancer may draw more first-line data and trials, with randomized results still aheadA further rise in the 10-year yield, now 5.04%·

Dates from 14 Verified Catalyst Calendar; odds only where a logged call in 15 sets them. Analysis

RED TEAM

Our outlook has not moved while the market fell six days running, as reported. If the sell-off spreads, the risk to small biotech may be larger than our rates line suggests. Analysis

AI & Technology Intelligence

Outlook: expiry clears, then earnings and the Fed · No. 052 · · About 1 min read

30 days. Monthly options expired Friday. Dell reports 11.24, Marvell 12.01, Salesforce 12.02, and the Fed meets 12.08 to 12.09, with Broadcom reporting 12.09. Huang is reported to have agreed to interviews with House committees on 12.01. Our scenario odds are unchanged. Analysis

60 days. Comments on Commerce’s remote-access rule are due 01.19.2027. The new Congress convenes in January; we found no federal data center moratorium bill. Analysis

90 days. The big cloud buyers report December-quarter results and 2027 spending plans in late January. That is the first hard test of whether this sell-off reflects spending that is slowing. Speculation

RED TEAM

Markets can keep falling or recover long before any of these dates, and spending guidance can change between earnings reports.